California-based Renasant Bio announced its launch to advance next-generation disease-modifying treatments for autosomal ...

Nuclidium, a radiopharma company developing a proprietary copper-based theranostic platform, has announced the successful ...

Sino-American drug discovery firms TandemAI and Perpetual Medicines have merged.

Shares in US biotech Ultragenyx Pharmaceutical (Nasdaq: RARE) and its UK-based partner Mereo BioPharma (Nasdaq: MREO) tumbled ...

Chinese cell therapy developer NK CellTech has raised nearly 100 million renminbi ($14 million) in an extended series A+++ ...

BrainXell, a US biotechnology company developing iPSC-based CNS disease models and regenerative cell therapies, has announced ...

Lewy body dementia (LBD) remains one of the most overlooked and complex neurodegenerative conditions, but momentum is ...

Sino-American biopharma Ascentage Pharma announced that its proprietary novel Bcl-2 selective inhibitor lisaftoclax (APG-2575 ...

The US Food and Drug Administration (FDA) has approved US mRNA specialist Moderna supplemental Biologics License Application ...

French biotech Osivax has published results from a Phase IIa trial showing that its lead candidate OVX836, a broad-spectrum ...

China-based biotech Biocytogen has signed a global licensing agreement with oncology-focused BeOne Medicines (SHA: 688235), ...

The US Food and Drug Administration (FDA) has accepted for review Merck & Co’s New Drug Application (NDA) for ...